iFabric Corp. — Investor Presentation 2021

Jan 19, 2021

INVESTOR PRESENTATION JANUARY 19, 2021

TSX: IFA; OTC: IFABF A preliminary prospectus (the “Preliminary Prospectus”) containing important information relating to the securities described in this presentation (the “Investor Presentation”) has been filed with the securities regulatory authorities in each province and territory of Canada (other than Quebec). A copy of the Preliminary Prospectus, and any amendment, is required to be delivered with this document. The Preliminary Prospectus is still subject to completion. There will not be any sale or any acceptance of an offer to buy the securities until a receipt for the final prospectus has been issued. This Investor Presentation does not provide full disclosure of all material facts relating to the securities offered. Investors should read the Preliminary Prospectus, the final prospectus and any amendment for disclosure of those facts, especially risk factors relating to the securities offered, before making an investment decision.

==> picture [443 x 270] intentionally omitted <==

==> picture [443 x 270] intentionally omitted <==

DISCLAIMER

Included in this Investor Presentation is certain forward-looking information related to iFabric Corp. (the “Company”), as such term is defined under applicable Canadian securities laws. This information relates to future events or future performance and reflects management's expectations and assumptions regarding the growth, results of operations, performance and business prospects and opportunities of the Company. Such forward-looking information reflects management's current beliefs and is based on information currently available to management of the Company and a number of assumptions that management believed were reasonable on the day such forward-looking information was presented. Refer, in particular, to the relevant sections of the Investor Presentation, the Prospectus and the documents incorporated by reference therein, for a discussion of certain assumptions management has made in presenting forward-looking information, which sections are incorporated by reference therein. In some cases, forward-looking information can be identified by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "intend", "believe", "estimate", "predict", "potential", "continue" or the negative or grammatical variations of these terms or other similar expressions concerning matters that are not historical facts. In particular, information regarding the Company's future operating results and economic performance is forward-looking information. A number of factors could cause actual events or results to differ materially from the events and results discussed in the forward-looking information. See "Risk Factors" in the Preliminary Prospectus.

Forward-looking information relates to analyses and other information that are based on forecasts of future results, estimates of amounts not yet determinable and other uncertain events. Forward-looking information, by its nature, is based on assumptions, including those described below, and involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements to differ materially from those expressed in the forward-looking information. Any forecasts or forward-looking predictions or statements cannot be relied upon due to, among other things, changing external events and general uncertainties of the business. Results indicated in forward-looking information may differ materially from actual results for a number of reasons, including without limitation: completion of the Offering; the intended use of proceeds from the Offering; expectations regarding future revenues, earnings, capital expenditures and operating and other costs; business strategy and objectives; market trends; the sufficiency of cash and working capital for future operating activities; expectations for other economic, business, regulatory and/or competitive factors related to the Company or the industries it competes in generally; anticipated production capacity; and other events or conditions that may occur in the future.

Investors are cautioned that forward-looking information is not based on historical facts but instead is based on reasonable assumptions and estimates of management of the Company at the time they were made and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Such factors include, among others, risks relating to competition; general economic conditions and consumer spending; reliance on key licensing and distribution agreements; economic dependence on key customers; dependence on key personnel; rapid technological advancements in the industry; the Company's ability to maintain proprietary protection of its intellectual property; future changes in government regulation, dependence on customer adoption; and the expected or potential impact of the novel coronavirus ("COVID-19") pandemic, as well as the risk factors described under the heading "Risk Factors" in the Preliminary Prospectus. Prospective purchasers are cautioned that the foregoing list is not exhaustive of all factors and assumptions which may have been used. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such forward-looking information and statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such information and statements. Accordingly, prospective purchasers should not place undue reliance on forward-looking information and statements, including the documents incorporated herein by reference, as statements containing forward-looking information involve significant risks and uncertainties and should not be read as guarantees of future results, performance, achievements, prospects and opportunities. The forward-looking information and statements contained herein are presented for the purposes of assisting prospective purchasers in understanding the Company's expected financial and operating performance and the Company's plans and objectives and may not be appropriate for other purposes.

All forward-looking information in this Investor Presentation, the Preliminary Prospectus and the documents incorporated by reference into the Preliminary Prospectus, is qualified by these cautionary statements. The forwardlooking information is made only as of the date that such information is made, and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required under applicable securities regulations.

An investment in the Units (as defined in the Preliminary Prospectus) is highly speculative and involves a high degree of risk, and should only be made by persons who can afford the total loss of their investment. Investors should carefully consider the risk factors described in the Preliminary Prospectus before purchasing the Units. Prospective investors are advised to consult their legal counsel and other professional advisors in order to assess income tax, legal and other aspects of the investment. See "Forward-Looking Information" and "Risk Factors" in the Preliminary Prospectus.

Prospective purchasers should rely only on the information contained or incorporated by reference in the Preliminary Prospectus. The Company and the Underwriters (as defined in the Prospectus) have not authorized anyone to provide prospective purchasers with information different from that contained or incorporated by reference in the Preliminary Prospectus. The Underwriters are offering to sell and seeking offers to buy the Units only in jurisdictions where, and to persons to whom, offers and sales are lawfully permitted. Prospective purchasers should not assume that the information contained in the Preliminary Prospectus is accurate as of any date other than the date on the cover page of the Preliminary Prospectus.

Prospective purchasers are advised to consult their own tax advisors regarding the application of Canadian and U.S. federal income tax laws to their particular circumstances, as well as any other provincial, state, foreign and other tax consequences of acquiring, holding or disposing of the Units, including the Canadian federal income tax consequences applicable to a foreign controlled Canadian corporation that acquires the Units.

This Investor Presentation is qualified in its entirety by reference to, and must be read in conjunction with, the information contained in the Preliminary Prospectus. A prospective investor is not entitled to rely on parts of the information contained in this presentation to the exclusion of others.

COMPANY HIGHLIGHTS

==> picture [32 x 33] intentionally omitted <==

INTELLIGENT FABRICS THAT ADDRESS UNMET CONSUMER AND MEDICAL NEEDS Patented antimicrobial technologies for performance apparel

Flagship PROTX2® AV chemistry kills viruses and bacteria: 3[rd] party tested against COVID-19 Sustainable water repellent, moisture wicking and UV protection among suite of technologies

==> picture [32 x 32] intentionally omitted <==

ADVANCED CLAIM US EPA APPROVAL EXPECTED TO BE MAJOR CATALYST

In process of advanced US EPA claim registration that would create a step change in demand for our products

==> picture [32 x 32] intentionally omitted <==

GLOBAL PANDEMIC - CONSUMER TRENDS CREATE MASSIVE UPSIDE POTENTIAL

Experiencing significant growth in 2021 driven by dramatic ramp up from Intelligent Fabric Division

==> picture [32 x 33] intentionally omitted <==

MAJOR CUSTOMERS

Under Armour, Careismatic Brands, Lululemon, Walmart, Target, The North Face, Hanes, Kohl’s and Amazon are among our current top customers

==> picture [32 x 33] intentionally omitted <==

MANAGEMENT ALIGNED

Management ownership is 74%+ of the Company

==> picture [62 x 14] intentionally omitted <==

| 2021 Investor Presentation | 3

*Based on revenues from the quarter ended June 30, 2020

MANAGEMENT

==> picture [127 x 127] intentionally omitted <==

HYLTON KARON

Group President & CEO

Graduated from Philadelphia University with a BSC degree in textile marketing and management, and now has over 35 years of experience in product development and marketing. Hylton’s creative ability has resulted in the development of many successful and patented products which are sold both in North America and internationally.

==> picture [127 x 127] intentionally omitted <==

GIANCARLO BEEVIS

President & CEO | IFTNA

A graduate with an Honours B.A. from York University, Giancarlo has been involved with the company for 15 years, contributing expert knowledge and is instrumental in the brand development of Intelligent Fabric Technologies North America. Giancarlo oversees the strategic direction of IFTNA and the development of products, brands and technologies.

==> picture [127 x 127] intentionally omitted <==

HILTON PRICE

Group Chief Financial Officer

A Chartered Professional Accountant with over 40 years of experience covering a variety of industries and business. Hilton has been involved in most elements of the group's strategic planning and isresponsible for financial oversight since the groups inception.

==> picture [127 x 127] intentionally omitted <==

JASON GARAY

Chief Science Officer | IFTNA

Mr. Garay is the VP of Analytics and Informatics at Cancer Care Ontario (CCO). Jason was previously the Director, Communicable Disease Prevention and Control at Public Health Ontario. He is an Adjunct Professor at the University of Toronto and holds an MHSc in Community Health and Epidemiology, a BASc in Occupational and Public Health, and a BSc (Honours) in Statistics and Psychology.

==> picture [62 x 14] intentionally omitted <==

| 2021 Investor Presentation | 4

BOARD OF DIRECTORS

Dr. Mark Cochran PhD | Chairman

Dr. Cochran is Executive Director of Johns Hopkins Medicine. His experience spans all levels of the drug discovery and development value chain, including operational and executive roles in the healthcare, venture capital, pharmaceutical, and biotech industries.

Hylton Karon Director

Mr. Karon is the Group President and CEO of iFabric Corp.

Mark Greenspan CA, CBV | Director

Mr. Greenspan was CFO of The Medipattern Corporation from September 2002 until February 2010. Prior to that, he spent 18 years at Scotiabank in various executive capacities. Prior to joining Scotiabank, he spent 8 years at KPMG where he specialized in mergers and acquisitions.

Hilton Price

Director

Mr. Price is the CFO of iFabric Corp.

Cameron Groome Director

Cameron has served on the Microbix Board of Directors and Advisory Committee since 2012, and was appointed CEO in 2017. He has more than 25 years of experience in senior life sciences and finance roles and has been an executive, director, and advisor for public and private companies.

Giancarlo Beevis

Director

Mr. Beevis is the President and CEO of IFTNA, a division of iFabric Corp.

==> picture [62 x 14] intentionally omitted <==

| 2021 Investor Presentation | 5

TWO DIVISIONS

Socially responsible fabric technologies as well as intimates and wardrobe solutions

INTELLIGENT FABRIC TECHNOLOGIES NORTH AMERICA INC. | IFTNA

==> picture [90 x 108] intentionally omitted <==

Revenue Stream #1 Performance additives for textiles. Including antimicrobial and antiviral textiles as well as solutions for medical, athletic, military, consumer & corporate apparel, bedding, linens and other categories.

Revenue Stream #2 Manufacturing private label performance apparel

Revenue Stream #3 Launching own brand of performance and travel apparel as well as personal protective equipment

COCONUT GROVE INTIMATES

==> picture [105 x 109] intentionally omitted <==

Coconut Grove Intimates has been developing and supplying the fashion industry with unique and superior intimate and sleepwear apparel collections.

Revenue Stream #1 Private label, Maidenform and in-house brands sold online and in brick and mortar stores.

Revenue Stream #2 Supply brands and distribute products for some of the most well known intimates brands globally.

==> picture [62 x 14] intentionally omitted <==

| 2021 Investor Presentation | 6

IFTNA TECHNOLOGY PORTFOLIO

IFTNA has developed a number of products that are partnered with household brands

==> picture [122 x 43] intentionally omitted <==

==> picture [127 x 26] intentionally omitted <==

==> picture [87 x 33] intentionally omitted <==

==> picture [99 x 22] intentionally omitted <==

==> picture [114 x 44] intentionally omitted <==

==> picture [108 x 38] intentionally omitted <==

==> picture [123 x 39] intentionally omitted <==

PROTX2[®] AV

Antiviral, antibacterial & anti-odour

PROTX2[® ]

Antibacterial, antimicrobial & anti-odour REPELTX ECO PLUS Fluorine free water repellent OMEGA[+] Accelerated joint & muscle recovery TEMP[+X] Thermo and cooling regulator

ECOTX

Metal-free antimicrobial agent

DREAMSKIN[®]

Encourages healthy & hydrated skin

==> picture [39 x 29] intentionally omitted <==

==> picture [81 x 15] intentionally omitted <==

==> picture [125 x 58] intentionally omitted <==

==> picture [120 x 18] intentionally omitted <==

==> picture [59 x 48] intentionally omitted <==

==> picture [93 x 40] intentionally omitted <==

imPRINT

APOLLO Body odour neutralizer

DRIFORCE Evaporation enhancement ENGUARD Insect repellent DRYTX[®] Moisture wicking technology

UVTX Superior UV protection

imPRINT

Wicks away moisture using fabric gateways exposing logos and patterns

==> picture [62 x 14] intentionally omitted <==

| 2021 Investor Presentation | 7

==> picture [296 x 60] intentionally omitted <==

IFTNA’S FLAGSHIP TECHNOLOGY

WORLDWIDE CHALLENGES

A GLOBAL PANDEMIC

• Amid the COVID-19 crisis, the global market for Antimicrobial Textiles estimated at US$8.5 Billion in the year 2020, is projected to reach a revised size of US$11.5 Billion by 2027

• The U. S. Accounts for Over 29.4% of Global Market Size in 2020, While China is Forecast to Grow at a 4.2% CAGR for the Period of 2020-2027

HEALTHCARE ASSOCIATED INFECTIONS (HAI’S)

• Now one of the top 10 leading causes of deaths in the developed world (CDC, NIH)

• Textiles are a major source of HAI-causing pathogens and yet there is no effective way to keep them free of these pathogens during use

• Healthcare providers’ uniforms can be vectors that spread infections

CONSUMER DESIRE

• The consumer desire for eco-friendly sustainable controlled odour solutions that allow for more wear and less washing

• 92% of hospital privacy curtains are contaminated with multiple infectious bacteria

• 100,000 deaths from hospital HAI’s last year in the United States

www.ncbi.nlm.nih.gov/pmc/articles/PMC6245375/

www.ncbi.nlm.nih.gov/pmc/articles/PMC4180417/

www.ncbi.nlm.nih.gov/pubmed/22464039

https://www.researchandmarkets.com/reports/5029859/antimicrobial-textiles-global-markettrajectory?utm_source=MC&utm_medium=Email&utm_code=mzr38yrl8&utm_ss=17&utm_campaign=1404873+-+Antimicrobial+Textiles++Global+Market+Trajectory+%26+Analytics&utm_exec=adke277mtd

==> picture [62 x 14] intentionally omitted <==

| 2021 Investor Presentation | 8

==> picture [296 x 60] intentionally omitted <==

PROTX2[® ] is a breakthrough in antibacterial, antimicrobial and anti-odour protection. When treated, each fiber is fundamentally transformed through PROTX2[®] ’s technology providing proprietary protection.

THE BREAKTHROUGH

PROTX2[®] in different dosages can be used in two distinct ways

HEALTHCARE, HOSPITALITY & FOOD SERVICE 1 as an antimicrobial, antibacterial, 2 and anti-odour agent

ATHLEISURE & SPORTSWEAR as an anti-odour agent

==> picture [378 x 253] intentionally omitted <==

==> picture [378 x 252] intentionally omitted <==

==> picture [62 x 14] intentionally omitted <==

| 2021 Investor Presentation | 9

==> picture [301 x 103] intentionally omitted <==

METAL-FREE

ANTIVIRAL, ANTIBACTERIAL & ANTI-ODOUR AGENT

PROTX2[®] AV is our newest patent pending anti-viral, antibacterial, and anti-odour textile technology. Test results show its innovative textile technology is proven to destroy SARSCoV2 and disable the virus from replicating. PROTX2[®] AV broad spectrum antiviral properties may also reduce the risk and speed of contamination and transmission.

• An effective chemical solution for reducing the spread of nosocomial infections on soft and hard surfaces.

• PROTX2[®] AV is the world’s first antiviral textile technology proven to kill greater than 99.9% of SARS-COV-2 (COVID-19) in 10 minutes. To the knowledge of the Company, it is the world’s first antiviral, antibacterial and anti-odour technology seeking kill claim registration with the US EPA.

• 3[rd ] party certified by independent laboratories against COVID-19, MRSA, C-Diff, VRE, E. Coli, Norovirus, and H1N1.

• Currently selling a suite of products to Under Armour (sports masks, gaiters) and recently launched with a Canadian Big Box Retailer.

• Applications span beyond healthcare to hospitality, military, and sportswear industries.

==> picture [388 x 559] intentionally omitted <==

==> picture [62 x 14] intentionally omitted <==

| 2021 Investor Presentation | 10

PRIVATE BRAND LAUNCHES

==> picture [436 x 189] intentionally omitted <==

==> picture [448 x 245] intentionally omitted <==

Underit[®] is IFTNA’s privately owned brand, that specializes in developing forward thinking technology infused performance and travel apparel, with PROTX2[®] as the host of all our other technologies.

We have designed, developed and patented an extensive range of Mens, Womens, and Kids products including:

Underwear | Sports Bras | Base Layer | Tights/Leggings Shirts & Tops | Compression | Athleisure

FRONTLINE[®] is IFTNA’s healthcare driven privately owned brand, specializing in PROTX2[®] AV treated personal protective equipment including:

Masks | Gloves | Gowns | Other Necessary PPE

==> picture [62 x 14] intentionally omitted <==

| 2021 Investor Presentation | 11

COCONUT GROVE INTIMATES

Since 1992, we have continued to stay on top of market trends to design, develop and supply the fashion industry with unique solution bras and bra accessories for every possible occasion. CGI is part of a niche market with aging competition and room for significant growth.

==> picture [43 x 42] intentionally omitted <==

25+ YEARS OF PROFITABILITY

Over 25 years of profitable operations with gross margins over 50%

==> picture [143 x 160] intentionally omitted <==

==> picture [248 x 78] intentionally omitted <==

==> picture [143 x 161] intentionally omitted <==

==> picture [147 x 160] intentionally omitted <==

==> picture [147 x 161] intentionally omitted <==

==> picture [40 x 39] intentionally omitted <==

PRIVATE LABEL

Distribution across Canada & USA

MAJOR CUSTOMERS

FLAGSHIP RETAILERS

==> picture [47 x 46] intentionally omitted <==

PATENTS

Innovative registered patents as well as new patent pending products.

==> picture [85 x 35] intentionally omitted <==

==> picture [93 x 41] intentionally omitted <==

==> picture [96 x 40] intentionally omitted <==

----- Start of picture text -----

PRIVATE LABEL
----- End of picture text -----

==> picture [73 x 23] intentionally omitted <==

==> picture [95 x 25] intentionally omitted <==

==> picture [96 x 23] intentionally omitted <==

==> picture [62 x 14] intentionally omitted <==

| 2021 Investor Presentation | 12

UPCOMING MILESTONES

US EPA ADVANCED CLAIM REGISTRATION

Kill claim registrations are currently pending

OWNED BRAND LAUNCH - UNDERIT[®] & FRONTLINE[®]

Underit[®] travel and performance apparel line expected to launch Spring 2021

Frontline[®] personal protective equipment brand expected to launch Q1 2021

CLINICAL TRIALS WITH PROTX2[®] & REPELTX[®]

2 trials pending with 400 nurses in 2 major US hospital systems utilizing PROTX2[®] and RepelTX[®] technologies

EXPANDING CUSTOMER BASE AND RENEWED CUSTOMERS

Large pipeline of new customers and indications of reorders from clients

==> picture [62 x 14] intentionally omitted <==

| 2021 Investor Presentation | 13

PATENT PORTFOLIO

Our portfolio of innovative patents answer today’s market trends

TECHNOLOGIES

==> picture [106 x 23] intentionally omitted <==

PATENT PENDING

PROTX2[®] AVGuard

Our proprietary laundry additive with antiviral, antibacterial and anti-odour properties.

==> picture [112 x 40] intentionally omitted <==

PATENT PENDING PROTX2[®] AV

Our antiviral, antibacterial and anti-odour agent.

UNDERWEAR

MASKS

BRA SOLUTIONS

PATENT PENDING

MESH SLING

Using the most advanced construction techniques

and materials, we’ve created a mesh sling that provides optimum support and comfort.

==> picture [151 x 117] intentionally omitted <==

==> picture [110 x 85] intentionally omitted <==

----- Start of picture text -----

Outer Inner
Filter
----- End of picture text -----

PATENT PENDING SLOTTED MASK Triple layer constructed protective mask.

==> picture [100 x 101] intentionally omitted <==

PATENTED

BREAST LIFT

The perfect braless solution with a unique tab design providing customizable lift and a contoured natural shape.

PATENT PENDING

2-SIDED FLY

Our 2-sided patented fly design caters to the wearer’s needs, whether they are left or right-handed, while providingall day comfort andsupport.

==> picture [114 x 147] intentionally omitted <==

PATENT PENDING

HAT MASK

A protective mask designed with a clip feature to attach to hats.

==> picture [135 x 101] intentionally omitted <==

PATENT PENDING

REVERSIBLE BRA

1 bra with 2 colour choices (nude and black) designed with double-sided silicone wings and dyed to match wing covers.

==> picture [62 x 14] intentionally omitted <==

| 2021 Investor Presentation | 14

IN THE MEDIA

In light of the current worldwide pandemic, consumers and industry leaders have shown explosive interest for iFabric's innovative SARs CoV2 destroying technology PROTX2®AV sparking worldwide media coverage shown on the largest media outlets since our launch just this year.

==> picture [671 x 512] intentionally omitted <==

==> picture [62 x 14] intentionally omitted <==

| 2021 Investor Presentation | 15

THANK YOU!

HYLTON KARON

HILTON PRICE

GIANCARLO BEEVIS

Group President & CEO HyltonK@iFabricCorp.com 905.752.0566 x201 905.752.0567

Chief Financial Officer Hilton.Price@rogers.com 647.465.6161 905.752.0567

President & CEO | IFTNA GC@iftna.com 905.752.0566 x202 905.752.0567

LEARN MORE AT WWW.IFABRICCORP.COM

INVESTOR RELATIONS

TINA BYERS

JEAN-FRANCOIS DUBÉ (QUEBEC)

GARY PERKINS

905.330.3275 Tina@adcap.ca 514.233.9551 JFDube@mac.com

416.882.0020 GaryPerkins@Rogers.com

525 Denison Street, Markham Ontario L3R1B8 905.752.0566 | www.ifabriccorp.com | info@ifabriccorp.com